Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension

Inclusion criteria

• The subject voluntarily signs the informed consent form.
• Male or female, aged ≥ 18 years and ≤ 75 years;
• Patients with mild to moderate hypertension;
• At the Screening and Baseline periods, the mean sitting office systolic blood pressure is > 130 mmHg, and the 24-hour mean systolic blood pressure assessed by ABPM at Screening is ≥ 130 mmHg and < 160 mmHg.

Exclusion criteria

• Secondary hypertension;
• Orthostatic hypotension;
• Type 1 diabetes or poorly controlled type 2 diabetes;
• Occurrence of any cardiovascular or cerebrovascular event within 6 months prior to screening;
• Presence of uncontrolled severe arrhythmia within 6 months prior to screening;
• Suspected allergy to the investigational drug or any of its components;
• Other diseases requiring Renin-Angiotensin-Aldosterone System (RAAS) inhibitor therapy, besides hypertension;
• Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria;
• Use of any medication affecting blood pressure within 4 weeks prior to screening, or planned use during the study period;